Alzheimer’s & Dementia

1. Our Research Network

Our Research Network

We conduct industry-sponsored and investigator-initiated trials in collaboration with four globally recognized centers of excellence:

University of Arizona
University of California San Diego (UC San Diego Health Sciences) – Alzheimer’s Disease Cooperative Study (ADCS)
University of Southern California – Alzheimer’s Therapeutic Research Institute (ATRI)
National Institute on Aging (NIA)
Alzheimer’s Clinical Trials Consortium
Brigham and Women’s Hospital
Cleveland Clinic Lou Ruvo Center for Brain Health
Keck School of Medicine of USC Alzheimer’s Therapeutic Research Institute

These partnerships give our volunteers first access to next-generation disease-modifying therapies, rigorous academic oversight, and a direct pipeline to the latest scientific breakthroughs.

2. Six Active Alzheimer’s Disease Trials

Six Active Alzheimer’s Disease Trials

We are presently enrolling six Phase 2–3 clinical studies covering:

Pre-clinical amyloid positivity — cognitively normal adults with elevated brain amyloid
Mild Cognitive Impairment (MCI) due to AD
Early symptomatic Alzheimer’s dementia
Plasma-guided prevention studies for at-risk carriers of APOE ε4
Anti-amyloid monoclonal antibody extensions
Novel anti-tau & neuroinflammation agents

Each protocol includes no-cost medical exams, advanced neuro-imaging (PET/MRI as required), and potential access to investigational disease-modifying treatments.

3. Biomarker-Driven Enrollment – Always Free to the Participant

Biomarker-Driven Enrollment – Always Free to the Participant

To be sure that memory changes are truly caused by Alzheimer’s pathology, a confirmed biomarker is mandatory for every study. All testing is performed on-site and FREE of charge:

Blood Test (SD)

What it Measures

Turn-around

Key Evidence

PrecivityAD2™

Aβ 42/40 ratio + %p-tau217 ± APOE proteotype

5-7 days

0.94 AUC-ROC and 90 % overall accuracy vs. amyloid-PET in a 583-patient multicenter validation.

Plasma p-tau217 immunoassay™

Phosphorylated tau 217 (early tau pathology)

7-10 days

91 % diagnostic accuracy in a 1,213-participant JAMA Neurology cohort

Plasma p-tau181 ELISA

Phosphorylated tau 181 (progressive tau tangle burden)

7-10 days

Sensitivity 94 % / specificity 72 % for distinguishing MCI due to AD in a 2,000-patient real-world study

No lumbar puncture or PET scan is required unless you request additional confirmation.

How it works: A quick blood draw in our Miami clinic is shipped to a CLIA-certified laboratory. Results return in about one week, letting you and our physicians know—confidently—whether you are eligible for one of our six active trials.

These partners help us ensure that our studies follow the highest standards and contribute meaningfully to Alzheimer’s research at a national and international level.

4. Participant Advantages

Participant Advantages

Memory Evaluation
Zero-cost care—all labs, imaging, study drugs, and physician visits are sponsored
Transportation support for those who need it
Advance the science—your involvement accelerates treatments that could help millions